| The publications listed on this website are provided as a courtesy only. The listed publications reference BioCryst drugs that are investigational in the U.S., meaning that they have not been approved or determined to be safe and effective by the FDA and are not commercially available in the U.S. |
Clinical Publications – Gout Program
Becker MA, Hollister AS, Terkeltaub R, Waugh A, et al. BCX4208 Combined with Allopurinol Increases Response Rates in Patients with Gout who Fail to Reach Goal Range Serum Urate on Allopurinol Alone: A Randomized, Double-Blind, Placebo-Controlled Trial – Presented at the 2011 American College of Rheumatology and the Association of Rheumatology Health Professionals (ACR/ARHP) Annual Scientific Meeting; 2011 Nov 4-9; Chicago, Illinois. Abstract & Slide Presentation
Hollister AS, Becker MA, Terkeltaub R, Waugh A, et al. BCX4208 Synergistically Lowers Serum Uric Acid (sUA) Levels when Combined with Allopurinol in Patients with Gout: Results of a Phase 2 Dose-Ranging Trial – Presented at the 2011 American College of Rheumatology and the Association of Rheumatology Health Professionals (ACR/ARHP) Annual Scientific Meeting; 2011 Nov 4-9; Chicago, Illinois. Abstract & Poster Presentation
Dobo S, Flynt A, Hollister A, Sheridan W. BCX4208, A Novel Urate-Lowering Therapy, Was Generally Safe and Well-Tolerated in Two 3-Week Studies in Gout Patients – Presented at Annual European Congress of Rheumatology (EULAR); 2011 May 25-28; London, UK. Abstract & Poster Presentation
Hollister A, Becker M, Terkeltaub R, Waugh A, Lyman S, Flynt A, Fitz-Patrick D. BCX4208 Shows Synergistic Reductions in Serum Uric Acid in Gout Patients When Combined with Allopurinol – Presented at Annual European Congress of Rheumatology (EULAR); 2011 May 25-28; London, UK. Abstract & Poster Presentation
Fitz-Patrick D, Drummond W, Pappas J, Hollister A. Effects of a Purine Nucleoside Phosphorylase Inhibitor, BCX4208, on the Serum Uric Acid Concentrations in Patients with Gout - Presented at American College of Rheumatology (ACR); 2010 Nov; Atlanta, Georgia. Abstract & Poster Presentation
Other Publications – Gout Program
Pearson PG, Bantia S, Harman LA. Nonclinical Drug-Drug Interaction (DDI) Profile of BCX4208, an Oral, Once-Daily, Novel Nonmetabolized Enzyme Inhibitor for Chronic Management of Gout – Presented at the 2011 American College of Rheumatology and the Association of Rheumatology Health Professionals (ACR/ARHP) Annual Scientific Meeting; 2011 Nov 4-9; Chicago, Illinois. Abstract & Poster Presentation
Bantia S, Parker C, Upshaw R, Cunningham A, Kotian P, Kilpatrick JM, et al. Potent Orally Bioavailable Purine Nucleoside Phosphorylase Inhibitor BCX4208 Induces Apoptosis in B- and T-lymphocytes-a Novel Treatment Approach for Autoimmune Diseases, Organ Transplantation and Hematologic Malignancies. Int Immunopharmacol. 2010 Jul;10(7):784-90. Epub 2010 Apr 22. Article
Other Disease States Publications
Bantia S, Parker C, Upshaw R, Cunningham A, Zhang J, Kotian P, et al. BCX4208 (RO5092888), a Purine Nucleoside Phosphorylase (PNP) Inhibitor, is a Novel, Potent Orally Active Anti T- and B-Cell Agent – Presented at The American Society of Hematology 50th Annual Meeting & Exposition (ASH); 2008 Dec 6-9; San Francisco, California. Abstract & Poster Presentation
Gomes J, Georgy A, Passe S, Bantia S, Farid A, Wolff G. A Phase 2 Study of the Purine Nucleoside Phosphorylase (PNP) inhibitor RO5092888 (BCX4208) in Patients with Moderate to Severe Chronic Plaque Psoriasis: Safety, Tolerability and Lymphocyte Effects – Presented at The American Society of Hematology 50th Annual Meeting & Exposition (ASH); 2008 Dec 6-9; San Francisco, California. Abstract & Poster Presentation